Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/≤3 nM), similar activity against PDGFRβ and c-Kit, selective more for VEGFR than PDGFR-α (36-fold), CSF-1R (110-fold), and Flt3 (1000-fold) in HUVEC cells.
More Information Supplier Page
Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/≤3 nM), similar activity against PDGFRβ and c-Kit, selective more for VEGFR than PDGFR-α (36-fold), CSF-1R (110-fold), and Flt3 (1000-fold) in HUVEC cells.
More Information Supplier Page Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/≤3 nM), similar activity against PDGFRβ and c-Kit, selective more for VEGFR than PDGFR-α (36-fold), CSF-1R (110-fold), and Flt3 (1000-fold) in HUVEC cells.
More Information Supplier Page 
Perifosine is an oral-active, alkyl-phosphocholine Akt inhibitor with potential antineoplastic activity.
More Information Supplier Page
IOWH032, a synthetic CFTR inhibitor, has been investigated for the treatment of cholera, diarrhea, and secretory diarrhea.
More Information Supplier Page
FH535, a Wnt/β-catenin signaling and PPAR inhibitor, exhibits anti-tumor activities.
More Information Supplier Page
FH535, a Wnt/β-catenin signaling and PPAR inhibitor, exhibits anti-tumor activities.
More Information Supplier Page 
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.
More Information Supplier Page
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.
More Information Supplier Page 
BIBR 1532 is an effective, specific and non-competitive telomerase inhibitor (IC50: 100 nM, in a cell-free assay).
More Information Supplier Page
